Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01708629 |
Recruitment Status
:
Terminated
(Sponsor decision)
First Posted
: October 17, 2012
Last Update Posted
: December 22, 2015
|
Sponsor:
Amgen
Information provided by (Responsible Party):
Amgen
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review
by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
Recruitment Status : | Terminated |
---|---|
Actual Primary Completion Date : | August 2014 |
Actual Study Completion Date : | October 2015 |
Certification/Extension First Submitted : | April 14, 2015 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 | November 8, 2016 | January 6, 2017 |
2 | February 8, 2017 | March 28, 2017 |
3 | April 7, 2017 | May 18, 2017 |
4 | July 31, 2017 | August 30, 2017 |
5 | December 8, 2017 | January 8, 2018 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):